SCHEMBL2945468

SCHEMBL2945468

Cc1ccccc1-c1nncc2cc(Cl)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.48
KIT P10721 3/20 0.48
MAPK9 P45984 1/20 0.48
MAPK10 P53779 1/20 0.48
CYP3A4 P08684 1/20 0.46
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
LCK P06239 2/20 0.41
KDR P35968 2/20 0.41
PDE2A O00408 1/20 0.40
PDE10A Q9Y233 1/20 0.40
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952084 0.84 SCN9A (0.39) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2944602 0.84 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2945976 0.84 MAPK14 (0.60) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL600322 0.82 MAPK14 (0.46) MAPK14PDE2APDE10ACRHR1SCN9A
SCHEMBL29941671 0.81 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2944568 0.79 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL601354 0.78 MAPK14 (0.47) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2956155 0.77 MAPK14 (0.55) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2951418 0.75 MAPK14 (0.68) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2955979 0.73 TRPA1 (0.48) MAPK14KITMAPK9MAPK10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAPK14 293/4885KIT 1977/4885MAPK9 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.